SG11201809499UA - Processes for preparing phosphorodiamidate morpholino oligomers - Google Patents
Processes for preparing phosphorodiamidate morpholino oligomersInfo
- Publication number
- SG11201809499UA SG11201809499UA SG11201809499UA SG11201809499UA SG11201809499UA SG 11201809499U A SG11201809499U A SG 11201809499UA SG 11201809499U A SG11201809499U A SG 11201809499UA SG 11201809499U A SG11201809499U A SG 11201809499UA SG 11201809499U A SG11201809499U A SG 11201809499UA
- Authority
- SG
- Singapore
- Prior art keywords
- street
- international
- cambridge
- processes
- pct
- Prior art date
Links
- 241001635911 Sarepta Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- -1 PHOSPHORODIAMIDATE MORPHOLINO Chemical class 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/062—Organo-phosphoranes without P-C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 11111111111111111111111111111111111111111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/205513 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: CO7F 9/6558 (2006.01) CO7F 9/6561 (2006.01) (21) International Application Number: PCT/US2017/034284 (22) International Filing Date: 24 May 2017 (24.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/340,953 24 May 2016 (24.05.2016) US 62/357,134 30 June 2016 (30.06.2016) US (71) Applicant: SAREPTA THERAPEUTICS, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US). (72) Inventors: CAI, Bao; c/o Sarepta Therapeutics, Inc., 215 _ First Street, Cambridge, MA 02142 (US). MARTINI, Mitchell; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). SHIMABUKU, Ross; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA — 02142 (US). THOMAS, Katie; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). = = Agent: TRINQUE, Brian, C. et al.; Lathrop & Gage, LLP, 28 State Street, Boston, MA 02109 (US). (74) Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, — = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, — TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — 1-1 KM, ML, MR, NE, SN, TD, TG). M Published: ,-1 — in in with international search report (Art. 21(3)) 0 ei N (54) Title: PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS 1-1 0 (57) : Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described ei herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340953P | 2016-05-24 | 2016-05-24 | |
| US201662357134P | 2016-06-30 | 2016-06-30 | |
| PCT/US2017/034284 WO2017205513A1 (en) | 2016-05-24 | 2017-05-24 | Processes for preparing phosphorodiamidate morpholino oligomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809499UA true SG11201809499UA (en) | 2018-12-28 |
Family
ID=59078166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809499UA SG11201809499UA (en) | 2016-05-24 | 2017-05-24 | Processes for preparing phosphorodiamidate morpholino oligomers |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10961262B2 (en) |
| EP (2) | EP3464306B1 (en) |
| JP (1) | JP6987081B2 (en) |
| KR (1) | KR102504759B1 (en) |
| CN (1) | CN109311920B (en) |
| AU (1) | AU2017271524B2 (en) |
| BR (1) | BR112018074270B1 (en) |
| CA (1) | CA3024182A1 (en) |
| CO (1) | CO2018013827A2 (en) |
| DK (1) | DK3464306T3 (en) |
| FI (1) | FI3464306T3 (en) |
| HR (1) | HRP20240583T1 (en) |
| HU (1) | HUE066393T2 (en) |
| IL (1) | IL263033B2 (en) |
| LT (1) | LT3464306T (en) |
| MA (1) | MA45155A (en) |
| MD (1) | MD3464306T2 (en) |
| MX (1) | MX2018014162A (en) |
| PL (1) | PL3464306T3 (en) |
| PT (1) | PT3464306T (en) |
| RS (1) | RS65504B1 (en) |
| SA (1) | SA518400462B1 (en) |
| SG (1) | SG11201809499UA (en) |
| SI (1) | SI3464306T1 (en) |
| TW (1) | TWI737736B (en) |
| WO (1) | WO2017205513A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI541024B (en) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | Antisense nucleic acid |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| MA45362A (en) * | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE |
| TWI737736B (en) | 2016-05-24 | 2021-09-01 | 美商薩羅塔治療公司 | Processes for preparing phosphorodiamidate morpholino oligomers |
| US10875880B2 (en) * | 2016-05-24 | 2020-12-29 | Sarepta Therapeutics, Inc. | Processes for preparing oligomers |
| KR102523527B1 (en) * | 2016-06-30 | 2023-04-20 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Method for preparing phosphorodiamidate morpholino oligomers |
| MX2018014160A (en) * | 2016-06-30 | 2019-04-01 | Sarepta Therapeutics Inc | Processes for preparing phosphorodiamidate morpholino oligomers. |
| TWI812647B (en) * | 2017-09-25 | 2023-08-21 | 美商薩羅塔治療公司 | Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis |
| CN112955153A (en) | 2018-08-02 | 2021-06-11 | 达因疗法公司 | Muscle targeting complexes and their use for the treatment of dystrophinopathies |
| CN109704980B (en) * | 2019-02-16 | 2022-05-13 | 安徽大学 | Preparation method of (Z) -3-amino-2- (2-fluoro-3-methoxyphenyl) -2-ethyl crotonate |
| WO2021187392A1 (en) * | 2020-03-16 | 2021-09-23 | 国立大学法人東京医科歯科大学 | Heteronucleic acid containing morpholino nucleic acid |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| AU2022377070A1 (en) * | 2021-11-01 | 2024-04-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes for treating dystrophinopathies |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| JP3022967B2 (en) | 1985-03-15 | 2000-03-21 | アンチバイラルズ インコーポレイテッド | Stereoregular polynucleotide binding polymer |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| CA1339987C (en) | 1988-09-01 | 1998-08-04 | Robert Bruce Merrifield | Peptide synthesis method and solid support for use in the method |
| JP3572617B2 (en) | 1993-12-29 | 2004-10-06 | 藤沢薬品工業株式会社 | Pyrazolopyridine adenosine antagonist |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| DE60033927T2 (en) | 1999-05-04 | 2007-11-29 | Santaris Pharma A/S | L-RIBO-LNA ANALOGUE |
| EP1282699B1 (en) | 2000-05-04 | 2012-11-21 | Sarepta Therapeutics, Inc. | Splice-region antisense composition and method |
| EP1446412B1 (en) | 2001-09-04 | 2012-03-07 | Exiqon A/S | Novel lna compositions and uses thereof |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| WO2004044140A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceticals, Inc. | 2’-substituted oligomeric compounds and compositions for use in gene modulations |
| US7759513B2 (en) | 2003-02-21 | 2010-07-20 | Nigu Chemie Gmbh | Photolabile protective groups for improved processes to prepare oligonucleotide arrays |
| PL2206781T3 (en) | 2004-06-28 | 2016-06-30 | Univ Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US9371348B2 (en) | 2006-11-27 | 2016-06-21 | The Trustees Of The University Of Pennsylvania | Photocleavable oligonucleotide and uses thereof |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| EP2207779B1 (en) * | 2007-11-15 | 2014-04-09 | Sarepta Therapeutics, Inc. | Method of synthesis of morpholino oligomers |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| CN102625840A (en) | 2009-04-10 | 2012-08-01 | 肌肉学研究协会 | Tricyclo-DNA antisense oligonucleotides, compositions, and methods for the treatment of disease |
| RS58079B1 (en) | 2009-11-12 | 2019-02-28 | Univ Western Australia | Antisense molecules and methods for treating pathologies |
| TWI620756B (en) * | 2010-05-28 | 2018-04-11 | 薩羅塔治療公司 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| TWI463423B (en) | 2010-05-28 | 2014-12-01 | Poynt Corp | Method of using location information for advertising system based on 3-dimensional shapes |
| TWI541024B (en) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | Antisense nucleic acid |
| CA2813183C (en) * | 2010-09-30 | 2017-09-19 | Nippon Shinyaku Co., Ltd. | Morpholino nucleic acid derivatives |
| MX2013009191A (en) * | 2011-02-08 | 2013-11-04 | Charlotte Mecklenburg Hospital | Antisense oligonucleotides. |
| CN103889999B (en) | 2011-08-23 | 2021-06-01 | 皇家学习促进学会/麦吉尔大学 | Ion labeling for oligoribonucleotide synthesis |
| EP2581448B1 (en) | 2011-10-13 | 2015-01-28 | Association Institut de Myologie | Tricyclo-phosphorothioate DNA |
| WO2013074834A1 (en) | 2011-11-18 | 2013-05-23 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| CA2857664A1 (en) | 2011-11-30 | 2013-06-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides targeting within the smn2 pre-mrna for use ininduced exon inclusion in spinal muscle atrophy |
| ES2748868T3 (en) * | 2011-12-28 | 2020-03-18 | Nippon Shinyaku Co Ltd | Antisense nucleic acid |
| ES2741099T3 (en) | 2012-02-28 | 2020-02-10 | Agilent Technologies Inc | Method of fixing a counting sequence for a nucleic acid sample |
| CN102702265A (en) * | 2012-05-14 | 2012-10-03 | 天津特安化学科技有限公司 | Phosphorodiamidate morpholino oligomer synthetized by solid phase and method thereof |
| HUE042218T2 (en) * | 2013-03-14 | 2019-06-28 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy |
| KR20230116945A (en) * | 2013-03-14 | 2023-08-04 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Exon skipping compositions for treating muscular dystrophy |
| CN105307723A (en) | 2013-03-15 | 2016-02-03 | 萨勒普塔医疗公司 | Improved compositions for treating muscular dystrophy |
| US8999152B2 (en) * | 2013-03-15 | 2015-04-07 | Uop Llc | Process and apparatus for recovering and blending hydroprocessed hydrocarbons and composition |
| CN105228999B (en) * | 2013-05-24 | 2021-03-02 | 味之素株式会社 | Process for preparing morpholino oligonucleotides |
| EP3463363A4 (en) | 2016-05-24 | 2020-02-19 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| MA45362A (en) * | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE |
| TWI737736B (en) * | 2016-05-24 | 2021-09-01 | 美商薩羅塔治療公司 | Processes for preparing phosphorodiamidate morpholino oligomers |
| US10875880B2 (en) * | 2016-05-24 | 2020-12-29 | Sarepta Therapeutics, Inc. | Processes for preparing oligomers |
| HUE059843T2 (en) | 2016-12-19 | 2023-01-28 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
-
2017
- 2017-05-24 TW TW106117191A patent/TWI737736B/en active
- 2017-05-24 EP EP17731337.6A patent/EP3464306B1/en active Active
- 2017-05-24 SG SG11201809499UA patent/SG11201809499UA/en unknown
- 2017-05-24 WO PCT/US2017/034284 patent/WO2017205513A1/en active Application Filing
- 2017-05-24 MA MA045155A patent/MA45155A/en unknown
- 2017-05-24 MD MDE20190424T patent/MD3464306T2/en unknown
- 2017-05-24 CA CA3024182A patent/CA3024182A1/en active Pending
- 2017-05-24 SI SI201731516T patent/SI3464306T1/en unknown
- 2017-05-24 PT PT177313376T patent/PT3464306T/en unknown
- 2017-05-24 AU AU2017271524A patent/AU2017271524B2/en active Active
- 2017-05-24 LT LTEPPCT/US2017/034284T patent/LT3464306T/en unknown
- 2017-05-24 RS RS20240522A patent/RS65504B1/en unknown
- 2017-05-24 HR HRP20240583TT patent/HRP20240583T1/en unknown
- 2017-05-24 MX MX2018014162A patent/MX2018014162A/en unknown
- 2017-05-24 FI FIEP17731337.6T patent/FI3464306T3/en active
- 2017-05-24 CN CN201780030642.8A patent/CN109311920B/en active Active
- 2017-05-24 DK DK17731337.6T patent/DK3464306T3/en active
- 2017-05-24 KR KR1020187036634A patent/KR102504759B1/en active IP Right Grant
- 2017-05-24 US US16/302,443 patent/US10961262B2/en active Active
- 2017-05-24 PL PL17731337.6T patent/PL3464306T3/en unknown
- 2017-05-24 BR BR112018074270-8A patent/BR112018074270B1/en active IP Right Grant
- 2017-05-24 HU HUE17731337A patent/HUE066393T2/en unknown
- 2017-05-24 EP EP24161437.9A patent/EP4406600A3/en active Pending
- 2017-05-24 JP JP2018560662A patent/JP6987081B2/en active Active
-
2018
- 2018-11-15 IL IL263033A patent/IL263033B2/en unknown
- 2018-11-19 SA SA518400462A patent/SA518400462B1/en unknown
- 2018-12-19 CO CONC2018/0013827A patent/CO2018013827A2/en unknown
-
2021
- 2021-02-08 US US17/169,611 patent/US20220340605A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201809502YA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201805204WA (en) | Nicotine particle capsule | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
| SG11201900043TA (en) | Antibody formulations | |
| SG11201907199QA (en) | Cancer treatment | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases | |
| SG11201807478QA (en) | Methods and compositions for increased double stranded rna production | |
| SG11201909906QA (en) | Organic compounds |